B+
Bull case
25%
Probability
Target price
$10.80
+98.9% vs current
CVRX
CVRxFNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$8.50
+56.5% vs current
B-
Bear case
25%
Probability
Target price
$5.00
-7.9% vs current
AI sentiment snapshot
Latest data as of 2026-04-21
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Sentiment is cautiously constructive, not aggressively bullish. The strongest current evidence is the April 13 preliminary Q1 update, which showed better-than-February guidance revenue, stronger gross margin, more active implanting centers, and improving authorization metrics after the January CPT code transition [#8-K-2026-04-13] [#PR-2026-02-12] [#PR-2026-01-06]. But forward visibility is still limited: CVRx remains a low-coverage, small-cap medtech with ongoing losses, a single core commercial asset, and a longer-dated clinical-expansion thesis that is still only at the site-activation and enrollment stage [#PR-2026-01-22] [#PR-2026-02-12].
RankAlpha Sentiment Codex - 2026-04-21
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystMid-May Q1 2026 report is the nearest hard confirmation pointHigh impact
CVRx said on April 13, 2026 that Q1 2026 revenue is expected at $14.7-$14.8 million, gross margin about 87%, operating expense about $25 million, cash about $72.3 million, and full results are expected in mid-May; that print is the clearest near-term check on whether the reimbursement and center-expansion story is translating into cleaner growth and margin leverage [#8-K-2026-04-13].
2026-06-30eventBENEFIT-HF enrollment start is a credible expansion catalyst but still earlyHigh impact
CVRx initiated BENEFIT-HF in January 2026, describing a 2,500-patient trial across about 150 centers in the U.S. and Germany with CMS Category B IDE coverage, and the April 13 update said the first site was activated on March 31, 2026 with enrollment expected to begin in Q2 2026; enrollment progress would support the longer-term thesis that Barostim could address a population roughly three times larger, but this remains an early monitoring catalyst rather than a near-term outcomes event [#PR-2026-01-22] [#8-K-2026-04-13].
2026-09-30catalystCategory I CPT rollout can improve reimbursement predictability and adoption through 2026High impact
CVRx confirmed that Category I CPT codes for Barostim became effective January 1, 2026, replacing Category III codes, and later disclosed that its in-house Medicare Advantage 30-day prior-authorization approval rate improved from 31% in 2024 to 44% in 2025 and 50% in the first two months of 2026; if those early gains persist, the reimbursement friction that limited physician and hospital adoption should ease further over the next several quarters [#PR-2026-01-06] [#8-K-2026-04-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-21 • Updated nightlySource: Internal modelMethodology